课题基金 / 基金详情

Splicing factors as therapeutic targets for the treatment of ovarian cancer

Splicing factors as therapeutic targets for the treatment of ovarian cancer
剪接因子作为卵巢癌治疗靶点
批准号:
7634178
负责人:
WILLIAM T BECK
金额:
$31.41万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2013-02-28

项目摘要

项目成果

WILLIAM T BECK的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):上皮性卵巢癌(EOC)每年侵袭25000多名美国妇女,其中50%的妇女将死于这种疾病,特别是如果诊断为晚期疾病,这是很常见的。为了开发新的治疗方法,有必要更好地了解与肿瘤转化相关的分子事件。选择性剪接(AS)通过允许单个基因产生多种蛋白质同种异构体,在扩大后生动物蛋白质组学复杂性和适应内外环境变化方面起着重要作用。一般来说,与正常组织相比,肿瘤中更多的基因,特别是那些与肿瘤发生有关的基因,表现出不同的剪接形式。越来越多的证据表明,AS与肿瘤进展和/或转移有关,并可能参与其中。目前,导致癌症剪接改变的机制尚不清楚,但它们可能是由于顺式元件的突变,或者更可能是由于反式作用因子(如剪接因子)的变化。事实上,一些剪接因子,包括PTB和SRp20,在肿瘤中过度表达,其中一个,SF2/ASF,被证明是一个致癌基因。与正常卵巢上皮相比,PTB和SRp20在人卵巢肿瘤中过表达,而正常卵巢上皮中PTB要么不表达,要么表达水平很低,这些SFs的表达与这些肿瘤的恶性程度有关。通过siRNA体外敲除卵巢肿瘤细胞中的PTB,可显著抑制肿瘤细胞的生长、集落形成和侵袭性,导致卵巢肿瘤小鼠肿瘤生长减慢。我们的研究结果提供了原理证明,剪接因子可能是一类新的和未开发的癌症治疗靶点,至少对于EOC中的PTB,这是一种预后不佳且没有良好治疗选择的疾病,特别是对于晚期疾病。在本提案中,我们将重点关注PTB这一剪接因子和EOC这一肿瘤类型,并假设PTB是该疾病的可药物治疗靶点。为了验证我们的假设,我们建议开发一种基于细胞的高通量小分子文库筛选,以鉴定干扰PTB活性的小分子,然后研究这些鉴定的小分子是否能够抑制卵巢肿瘤的生长。为此,我们提出了三个具体目标:(1)开发和优化专有的基于细胞的报告系统,以监测细胞中PTB的活性;(2)开发和优化小分子文库的高通量筛选(HTS),包括含有fda批准的小分子,天然来源的提取物或化学合成的化合物,以鉴定PTB抑制剂;(3)体外和体内对卵巢肿瘤细胞生长的有效小分子的验证。如果成功,我们的方法将验证PTB作为一种新的治疗靶点,并将确定一类基于操纵选择性剪接的新型小分子药物,用于治疗卵巢癌,以及可能的其他上皮性癌症。公共卫生相关性:上皮性卵巢癌(EOC)每年侵袭25,000多名美国妇女,其中50%的妇女将死于这种疾病,特别是如果诊断为晚期疾病,这是很常见的。如果成功,本文提出的研究将验证靶向剪接因子和替代剪接作为治疗卵巢癌和其他癌症的新治疗方法。在项目结束时,我们将识别出用于治疗这些癌症的新药物的小分子,这显然会对公众健康产生积极影响。
英文摘要
DESCRIPTION (provided by applicant): Epithelial ovarian cancer (EOC) strikes more than 25,000 American women annually, and >50% of these women will die from their disease, especially if diagnosed, as is common, with late-stage disease. To develop new therapies for this disease, it will be necessary to better understand the molecular events that are associated with the neoplastic transformation. Alternative splicing (AS), by allowing production of multiple protein isoforms from a single gene, plays a major role in expanding proteomic complexity in metazoans and adaptations to internal and external environmental changes. In general, more genes in tumors, especially those associated with tumorigenesis, exhibit alternative splice forms compared to normal tissues. There is mounting evidence that AS is associated with and possibly involved in tumor progression and/or metastasis. At present, the mechanisms leading to splicing alterations in cancer are poorly understood, but they are likely due either to mutations in cis-elements or, more likely, changes in trans-acting factors, such as splicing factors. Indeed, several splicing factors, including PTB and SRp20, are overexpressed in tumors and one, SF2/ASF, was shown to be an oncogene. PTB and SRp20 are overexpressed in human ovarian tumors, compared to normal ovarian epithelium, where PTB is either not expressed or expressed at very low levels, and expression of these SFs is associated with malignancy of these tumors. Knockdown of PTB in ovarian tumor cells in vitro by siRNA substantially suppressed tumor cell growth, colony formation, and invasiveness and led to slower tumor growth in mice bearing ovarian tumors. Our results provide proof-of-principle that splicing factors may be a class of novel and unexplored therapeutic targets for cancer treatment, at least PTB in EOC, a disease that has a dismal outcome and for which there are no good therapeutic options, especially for advanced-stage disease. In this proposal, we focus on one splicing factor, PTB, and one tumor type, EOC, and hypothesize that PTB is a druggable therapeutic target in this disease. To test our hypothesis, we propose to develop a cell- based high-throughput screen of small molecule libraries to identify small molecules that interfere with PTB activity and then study whether these identified small molecules are able to inhibit ovarian tumor growth. To this end, we offer three specific aims: (1) Develop and optimize a proprietary cell-based reporter system to monitor the activity of PTB in the cell; (2) Develop and optimize a high throughput screen (HTS) of small molecule libraries, including those containing FDA-approved small molecules as well as extracts from natural sources or compounds generated by chemical synthesis to identify PTB inhibitors; and (3) Validation of effective small molecules on ovarian tumor cell growth in vitro and in vivo. If successful, our approach will validate PTB as a novel therapeutic target and will identify a novel class of small molecule drugs based on the manipulation of alternative splicing for the treatment of ovarian cancer, and possibly other epithelial cancers. PUBLIC HEALTH RELEVANCE: Epithelial ovarian cancer (EOC) strikes more than 25,000 American women annually, and >50% of these women will die from their disease, especially if diagnosed, as is common, with late-stage disease. If successful, the research proposed here will validate targeting of splicing factors and alternative splicing as a novel therapeutic approach to the treatment of ovarian and other cancers. At the end of the project period we would have identified small molecules leading to new drugs for the treatment of these cancers, and this will clearly have a positive impact on public health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Splicing factors as therapeutic targets for the treatment of ovarian cancer
Splicing factors as therapeutic targets for the treatment of ovarian cancer
Functions of MRP2 and MRP3 in Drug Disposition
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS
海外基金